Previous 10 | Next 10 |
2024-02-21 10:00:32 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming UBS concedes it wasn't bullis...
Eight new antibody discovery agreements incorporate Vaccinex’s powerful ActivMAb® Drug Discovery Platform ActivMab® platform enables the discovery and development of high value antibodies against challenging multi-pass membrane targets ROCHESTER, N.Y., Feb. 21, 20...
2024-02-19 08:02:11 ET Vaccinex Inc (VCNX) announced stock split at a ratio of 1-for-14 on 2024-02-20 ... Full story available on KlickAnalytics.com
2024-02-07 08:19:14 ET More on Vaccinex Financial information for Vaccinex Read the full article on Seeking Alpha For further details see: Vaccinex prices $3.7M PIPE financing
ROCHESTER, N.Y., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammat...
2024-01-10 17:37:03 ET More on Vaccinex Financial information for Vaccinex For further details see: Vaccinex files to sell 712,484 shares for holders
2023-12-04 11:25:49 ET More on Vaccinex Vaccinex slumps 29%, prices $9.6M equity Financial information for Vaccinex For further details see: Vaccinex says Nasdaq gives co extension to regain compliance with listing rule
Company Has Reassured Nasdaq of Actions It Plans to Take to Meet Minimum Bid Price Requirement Randomized Phase 2 Study in Alzheimer’s Disease on Schedule to Complete Treatment in June 2024 ROCHESTER, N.Y., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a cl...
2023-11-13 17:30:47 ET More on Vaccinex Vaccinex slumps 29%, prices $9.6M equity Financial information for Vaccinex For further details see: Vaccinex GAAP EPS of -$1.09, revenue of $0.02M
Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Company raised over $10 million of new financing during Q3 and early October 2023. ROCHESTER, N.Y., Nov. 13, 2023 (GL...
News, Short Squeeze, Breakout and More Instantly...
2024-04-17 01:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Soligenix Inc. (SNGX) rose 127.5% to $0.8782 on volume of 62,157,057 shares Trio Petroleum Corp. (TPET) rose 8.0% to $0.5571 on volume of 48,902,033 shares Organovo Holdings Inc. (ONVO) rose 36.3% to $1.3769 on volume of 34,819,187 sh...
Expect Topline Data for Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab for Alzheimer’s Disease in Q3 2024 Company raised $17.9 million of new financing during Q4 2023 and Q1 2024 ROCHESTER, N.Y., April 02, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clin...